Ember Therapeutics Announces Publication in Circulation of Data Validating Utility of BMP-7 to Regulate Scar Formation in the Heart

World News: . []

NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and other regenerative medicines, today announced that scientists have validated a molecular mechanism that regulates scar formation in the heart, a common manifestation of aging and nearly every form of heart disease. Additionally, scientist confirmed that a protein called bone morphogenetic protein 7 (BMP-7) can prevent the generation of fibrotic signals by cardiomyocytes and may be able to serve as a therapy for cardiac fibrosis. The data was published in the journal .

Tissue fibrosis is the leading cause of organ failure. There is a lack of effective therapies. Currently, the only cure for cardiac fibrosis is heart transplantation.

“This work validates that the use of BMP-7 as a unique therapeutic strategy to prevent cardiac fibrosis,” said Joseph Hernandez, Ember’s Executive Chairman. “Ember has an extensive patent portfolio of over 400 patents in the use of BMP-7 in fibrosis and other indications. We are delighted with this data and look forward to partnering our intellectual property in this area of severe clinical need,” added Mr. Hernandez.

Contact Information:
Betty Rose (investors)
brose@embertx.com

More news and information about Ember Therapeutics

Published By:

Globe Newswire: 17:22 GMT Monday 17th July 2017

Published: .

Search for other references to "ember" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers